INTRODUCTION
The functional expression of voltage-gated K + (Kv) channels has been investigated in human breast (1, 2) , gastric (3) and prostate (4, 5) cancer cells. Among the Kv channel subunits, Kv1.3 has been shown to be involved in the proliferation and apoptosis of breast and prostate cancer cells (2, (5) (6) (7) . However, there exists a discrepancy in the published data. Abdul et al. (2) did not detect immunostaining of Kv1.3 in normal human breast specimens, but detected increased staining of Kv1.3 in breast cancer specimens. On the other hand, Brevet et al. (7) found Kv1.3 is expressed less in cancerous breast tissues than in normal breast tissues. In order to clarify how the expression level of Kv1.3 depends on breast cancer tumorigenicity, we used immortalized human mammary epithelial cells (M13SV1 cells) and tumorigenic mammary epithelial cells (M13SV1R2 and M13SV1R2-N1 cells). These cell lines are useful in comparing the expression patterns of Kv1.3 because they originate from identical human mammary epithelial cells. Moreover, M13SV1R2 and M13SV1R2-N1 cells are weakly tumorigenic and highly tumorigenic, respectively. The tumorigenic properties of M13SV1R2 and M13SV1R2-N1 cells were previously analyzed using an in vivo tumorigenicity assay (8) . In the present study, we therefore examined how the relative expression levels of Kv1.3 correspond to the tumorigenicity of human mammary epithelial cells as well as to each stage of breast cancer.
RESULTS AND DISCUSSION

Relative mRNA expression of Kv1.3 in M13SV1, M13SV1R2 and M13SV1R2-N1 cells
Relative mRNA expression levels of the Kv1.3 subunit in M13SV1, M13SV1R2 and M13SV1R2-N1 cells were compared. As shown in Fig. 1A , the mRNA expression of Kv1.3 in weakly tumorigenic M13SV1R2 cells was significantly increased to a level approximately 4.3 times higher than normal M13SV1 cells; however, a decrease in mRNA expression of approximately 0.5-fold was observed in highly tumorigenic M13SV1R2-N1 cells compared to normal M13SV1 cells. The same expression profile for Kv1.3 was observed in prostate cancer cells (9) . The expression level was significantly increased in Gleason scores of 5-6 (GS5-6), and significantly decreased in the GS8-9 groups (9).
Expression of Kv1.3 mRNA in human breast cancer tissues
We compared the mRNA expression level of Kv1.3 in human breast cancer tissues at different stages to that in normal breast tissues. While the mRNA level of Kv1.3 was significantly increased in breast cancer stages I (n = 16), IIA (n = 13) and IIB (n = 10), it was not significantly different in stages IIIA (n = 9) and IIIB (n = 4). During the late stage of breast cancer, stage IIIC (n = 7), and the metastatic stage, stage IV (n = 5), the expression of Kv1.3 was significantly increased compared to the level of mRNA isolated from normal (stage 0, n = 10) breast tissues (Fig. 1B) .
Much effort has been spent to identify the tumor markers in breast cancer (10) . Through these efforts various cancer antigens (CA) have been identified as being specifically related to http://bmbreports.org breast cancer. Currently, 13 categories of specific molecular targets related to poor prognosis in early-stage breast cancer have been suggested, including CA15-3, CA27.29, carcinoembryonic antigen, human epidermal growth factor 2, estrogen and progesterone receptor, urokinase plasminogen activator and plasminogen activator inhibitor 1 (11) . The results from the present study suggest that the mRNA expression pattern of Kv1.3 varies depending on tumorigenicity and stage of breast cancer. In particular, Kv1.3 expression was increased in the early stages of breast cancer, stages I, IIA and IIB. Early detection of breast cancer is critical from a clinical perspective (12) . Therefore, Kv1.3 could be used as an early diagnostic marker for breast cancer, accompanying the many other known tumor markers.
Protein level of Kv1.3 in M13SV1, M13SV1R2 and M13SV1R2-N1 cells
Western blot analysis was performed using commercially available antibodies to determine if the Kv1.3 subunit is expressed as a protein. Proteins approximately 45-60 kDa in size were specifically labeled with Kv1.3 antibody while pre-incubation with peptide antigens supplied by the company blocked the labeling (data not shown). The relative protein expression of Kv1.3 normalized with beta-actin was measured using Western blot analysis. The protein level of the Kv1.3 subunit was significantly increased in tumorigenic M13SV1R2 and M13SV1R2-N1 cells compared to normal M13SV1 cells (Fig. 2) . Quantification analysis revealed that the protein level of Kv1.3 increased 1.5-fold in M13SV1R2 cells and two-fold in M13SV1R2-N1 cells, compared to normal M13SV1 cells (Fig.  2B) . Furthermore, we found Kv1.3 protein expression did not correlate with the level of Kv1.3 mRNA expression. This discrepancy between mRNA and protein expression is not an uncommon phenomena. As described by Nie et al. (13) and Chen et al. (14) , mRNA and protein levels are affected by many factors such as cellular and physical processes. Therefore, results are often inconsistent regarding the correlation of mRNA and protein expression. This could be due to translational regulation or differences in protein half-lives (13) . In any case, additional experiments are needed to elucidate the mechanism in these cells. http://bmbreports.org BMB reports 
Expression of Kv1.3 protein in human breast cancer tissues
We compared the protein expression level of Kv1.3 in T2 and T3 stage human breast caner tissues to that in normal breast tissues. As shown in Fig. 3 , Kv1.3 protein was absent or stained at low levels in human normal breast tissue, but was strongly stained in T2 and T3 stage infiltrating ductal carcinomas. This result implies the expression level of Kv1.3 protein is positively correlated to the stage of breast cancer.
The effect of a Kv channel blocker on M13SV1R2 and M13SV1R2-N1 cell proliferation
To determine whether the Kv1.3 subunit is involved in regulating cell proliferation, we performed an MTT assay on M13SV1, M13SV1R2 and M13SV1R2-N1 cells using the Kv channel blocker, tetraethylammonium (TEA). As shown in Fig.  4 , 10 mM TEA significantly blocked the proliferation of M13SV1R2 and M13SV1R2-N1 cells by approximately more than 50%. However, treatment with 10 mM TEA had no affect on normal M13SV1 cells. Kv channel blockers such as 4-aminopyridine, TEA and tetrapentylammonium inhibit the proliferation of colorectal carcinoma cells by altering intracellular Ca 2+ signaling (15) . Additionally, the K channel blockers dequalinium and amiodarone suppressed cell proliferation of MCF human breast cancer cells (2) . This result indicates Kv1.3 could be a molecular therapeutic target for breast cancer therapy. In the same manner, Genistein, a natural flavone derived from soy, inhibits proliferation of the human breast cancer cell lines MCF-7 and MDA-MB-231, which suggests its potential as a therapeutic agent for breast cancer (16) . NSAID activated gene, a member of the TGF-β superfamily, also acts as a tumor suppressor in different types of cancer such as breast cancer (17) .
Taken together, these findings demonstrate the expression level of Kv1.3 varies depending on the tumorigenicity and stage of cancer of human mammary epithelial cells. Furthermore, blocking Kv1.3 could provide a new therapeutic strategy for breast cancer therapy.
MATERIALS AND METHODS
Cell culture
M13SV1, M13SV1R2 and M13SV1R2-N1 cells were grown in MSU-1 medium supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY) and 50 mg/ml gentamicin (Sigma, St. Louis, MO) at 37 o C in incubators supplied with 5% CO2 (18) .
Total RNA extraction and real-time PCR
M13SV1, M13SV1R2 and M13SV1R2-N1 cell suspensions were used for total RNA extraction with TRIzol reagents (Sigma). DNase I (Invitrogen, Carlsbad, CA) was treated for 30 min at 37 o C to remove genomic DNA. RNA (2 μg) was reverse transcribed at 37 o C for 60 min using random hexamer primers and an M-MLV reverse transcription kit (Promega, Madison, WI). PCR mixtures consisted of the following: two μl of cDNA diluted by one quarter, 1X SYBR Green Master Mix (Applied Biosystems, Foster City, CA) and 0.2 μM forward (5'-CGCGGT CTACTTTGCCGAG-3') and reverse primers (5'-CATATCGCC GTAACCCACTGT-3') mixed to a final volume of 20 μl. The PCR reaction was performed as follows: (1) 
Western blot analysis
M13SV1, M13SV1R2 and M13SV1R2-N1 cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM NaF, 1 mM EGTA, 0.25% sodium deoxycholate (Sigma), 1% Nonidet P-40 (Amresco Inc., Solon, Ohio) and the protease inhibitors 1 mM phenylmethy sulfonylfluoride and 2 μg/ ml aprotinin (Sigma). Proteins (25-30 μg) were resolved by a 10% acrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA). Membranes were incubated with anti-Kv1.3 (1:400) (Alomone Laboratories, Jerusalem, Israel) or anti-β actin (1:1000) (Santa Cruz Biotechnology, CA, USA), followed by exposure to horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:5000) (Santa Cruz Biotechnology). Membranes were developed using an enhanced chemiluminescent detection kit (iNtRon Biotechnology, Gyeonggi, Korea).
Drug treatment and cell proliferation assay
An MTT assay was performed to evaluate cell growth. Briefly, 3 × 10 3 cells were seeded on a 96-well tissue culture plate. Cells were treated with 10 mM TEA the following day for three days. To allow formazan formation, 0.5 mg/ml methylthiazoltetrazolium (MTT) (Sigma) solution was added and the cells were incubated at 37 o C for four hours. The MTT solution was replaced by 200 μl of dimethylsulfoxide (Sigma) to dissolve the formazan crystals, and the optical density was determined at 490 nm using a microplate analyzer (Bio-rad).
cDNA panel and tissue array
A human breast cancer gene expression cDNA panel was obtained from OriGene Technologies, Inc. (Rockville, MD, USA) while breast cancer tissue arrays were obtained from US Biomax Inc (Rockville, MD, USA).
Immunohistochemistry
The tissue slide was baked on a vertical rack in a dry oven at 60 o C for 2 hours to remove the coated paraffin. The slide was immersed twice in xylene (Duksan, Gyeonggi, Korea) for 10 min and hydrated with 100%, 95% and 70% ethanol (Duksan). Antigen retrieval was performed using 1 mM EDTA (pH 8.0) at 100 o C for 15 min. The slide was blocked with 5% normal goat serum at room temperature for 2 hours followed by incubation with anti-Kv1.3 (1:500) (Alomone Laboratories, Jerusalem, Israel) overnight at 4 o C. The slide was washed with PBS the following day and incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories, Inc., Burlingame, CA) at room temperature for 2 hours. Vectastain Ⓡ ABC kit and DAB (Vector Laboratories, Inc.) were used to visualize the tissue slide according to manufacturer's instructions.
Statistical analysis
All data are presented as the mean ± standard error (s.e.) of each group. The Mann-Whitney U test and Kruskal-Wallis test were used for data analysis. Differences between mean values were considered significant when P ＜ 0.05, and the SAS program (Version 9.1) was used for statistical analysis.
